Eikon Therapeutics (EIKN) News
NASDAQ: EIKNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
4.74-0.02 (-0.42%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
EIKN news summary
We found 8 recent headlines mentioning Eikon Therapeutics (EIKN): 1 in the past week and 5 in the past 30 days, most often from GlobeNewswire, Nasdaq. For price context, EIKN is down 0.42% at $4.74. The most recent story, "Eikon Therapeutics Announces Clearance to Proceed with First-in-Human Phase 1/2 Study for Novel Androgen Receptor Antagonist EIK1006 in Advanced Metastatic Prostate Cancer", was published by GlobeNewswire on Nov 17, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Eikon Therapeutics headlines
- Eikon Therapeutics Announces Clearance to Proceed with First-in-Human Phase 1/2 Study for Novel Androgen Receptor Antagonist EIK1006 in Advanced Metastatic Prostate CancerMILLBRAE, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to…GlobeNewswire
- Eikon Therapeutics, Inc. Loss At -$86.112 Mln In Q3(RTTNews) - Eikon Therapeutics, Inc. (EIKN) revealed Loss for third quarter of -$86.112 millionNasdaqEIKN, LEN.B
- Eikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical UpdatesMILLBRAE, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to…GlobeNewswire
- Eikon Therapeutics to Participate in Multiple Investor Conferences in NovemberMILLBRAE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to…GlobeNewswire
- Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology CongressMILLBRAE, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to…GlobeNewswire
- Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology CongressMILLBRAE, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to…GlobeNewswire
- Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology CongressPresentations to cover updates across Eikon’s clinical pipeline including:GlobeNewswire
- HC Wainwright & Co. Initiates Coverage of Eikon Therapeutics with Buy RatingFintel reports that on October 16, 2026, HC Wainwright & Co. initiated coverage of Eikon Therapeutics (NASDAQGS:EIKN) with a Buy recommendation. Prior to this rating action, Eikon Therapeutics closed…Nasdaq